Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-dose folic acid versus standard folic acid supplementation in methotrexate-treated rheumatoid arthritis
ACTRN12610000739011Phase 4Completed
- Sponsor
- Associate Professor Lisa Stamp
- Start
- Feb 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of folic acid and methotrexate in rheumatoid arthritis (RA) (2 arms), sponsored by Associate Professor Lisa Stamp. Primary endpoints: Change in DAS28 at 6 months and Occurrence of methotrexate-associated adverse effects. Started Feb 2011; status: completed.
02
Drugs
folic acidmethotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ACTRN12610000739011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000739011.